These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 34537075)

  • 1. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China.
    Zhu Y; Sun P; Wang K; Xiao S; Cheng Y; Li X; Wang B; Li J; Yu W; Cheng Y
    Cancer Cell Int; 2021 Sep; 21(1):503. PubMed ID: 34537075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Lenvatinib Combined With PD-1 Inhibitors Plus TACE for Unresectable Hepatocellular Carcinoma Patients in China Real-World.
    Li X; Fu Z; Chen X; Cao K; Zhong J; Liu L; Ding N; Zhang X; Zhai J; Qu Z
    Front Oncol; 2022; 12():950266. PubMed ID: 35860582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
    Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
    Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.
    Wu XK; Yang LF; Chen YF; Chen ZW; Lu H; Shen XY; Chi MH; Wang L; Zhang H; Chen JF; Huang JY; Zeng YY; Yan ML; Zhang ZB
    EClinicalMedicine; 2024 Jan; 67():102367. PubMed ID: 38169778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study.
    Xia D; Bai W; Wang E; Li J; Chen X; Wang Z; Huang M; Huang M; Sun J; Yang W; Lin Z; Wu J; Li Z; Yang S; Zhu X; Chen Z; Zhang Y; Fan W; Mai Q; Ding R; Nie C; Feng L; Li X; Huang W; Sun J; Wang Q; Lv Y; Li X; Luo B; Wang Z; Yuan J; Guo W; Li K; Li B; Li R; Yin Z; Xia J; Han G
    Liver Cancer; 2022 Jul; 11(4):368-382. PubMed ID: 35978600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.
    Sun L; Xu X; Meng F; Liu Q; Wang H; Li X; Li G; Chen F
    Front Oncol; 2022; 12():980214. PubMed ID: 36249023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients.
    Yang X; Chen B; Wang Y; Wang Y; Long J; Zhang N; Xue J; Xun Z; Zhang L; Cheng J; Lei J; Sun H; Li Y; Lin J; Xie F; Wang D; Pan J; Hu K; Guan M; Huo L; Shi J; Yu L; Zhou L; Zhou J; Lu Z; Yang X; Mao Y; Sang X; Lu Y; Zhao H
    Hepatol Int; 2023 Jun; 17(3):709-719. PubMed ID: 36753026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Transarterial Chemoembolization Plus Lenvatinib with or Without Tislelizumab as the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Jiang J; Zhang H; Lai J; Zhang S; Ou Y; Fu Y; Zhang L
    J Hepatocell Carcinoma; 2024; 11():1607-1622. PubMed ID: 39206422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination treatment strategy of lenvatinib for hepatocellular carcinoma: a real-world study.
    Chen J; Xiong P; Nie M; Pan Y; Wang J; Hu D; Zhou Z; Zhang Y; Chen M; Xu L
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2491-2500. PubMed ID: 35752744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis.
    Liu JN; Li JJ; Yan S; Zhang GN; Yi PS
    Front Oncol; 2023; 13():1074793. PubMed ID: 36910612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Cancer Rep (Hoboken); 2023 Jan; 6(1):e1679. PubMed ID: 35822407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study.
    Li Q; Cao M; Yuan G; Cheng X; Zang M; Chen M; Hu X; Huang J; Li R; Guo Y; Ruan J; Chen J
    Front Oncol; 2022; 12():809709. PubMed ID: 35280760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.
    Wang Q; Ji X; Sun J; Zhang A; Jia J; Zhang T; Li W; Duan X
    Int J Radiat Oncol Biol Phys; 2024 Dec; 120(5):1363-1376. PubMed ID: 38583495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
    Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.
    Wang BC; Kuang BH; Lin GH
    Target Oncol; 2024 Mar; 19(2):203-212. PubMed ID: 38289445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
    Qu S; Zhang X; Wu Y; Meng Y; Pan H; Fang Q; Hu L; Zhang J; Wang R; Wei L; Wu D
    Front Oncol; 2022; 12():874473. PubMed ID: 35530353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.